Figure 2From: The use of integrase inhibitors in treatment-experienced patients Virologic outcome in the BENCMRK studies stratifying by previously exposure to Darunavir/Ritonavir and Enfuvirtide. Nothe a near 90% response rate among first time users of Raltegravir, Darunavir/Ritonavir and Enfuvirtide [14, 29, 38].Back to article page